Synthesis and antitumor evaluation of new heterocyclic systems

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Cancer is a leading cause of death worldwide. In 2012 about 14.1 million new cases of cancer occurred globally and it caused about 8.2 million deaths or 14.6 % of human deaths. There is much more necessity to design and synthesize the most potent anticancer agents for cancer chemotherapy. It is most important that synthesized compounds do not show any activity on the normal human embryonic kidney cells, HEK-293. These type of compounds only can act as valuable drugs for cancer disease to the future generations. In future, some novel therapies were also used for the inhibition of cancer cell lines. Despite the introduction of new anticancer drugs, such as antimetabolites (capecitabine) and topoisomerase I inhibitors, the management of advanced neck cancer remains challenging. During the past years, interest has focused more on novel agents with a more targeted mechanism of the action. Targeted therapy aims to specifically act on a well defined target or biologic pathway that, when inactivated, causes regression or distraction of the malignant process.